glimepiride and sitagliptin phosphate

glimepiride has been researched along with sitagliptin phosphate in 51 studies

Research

Studies (51)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (1.96)	29.6817
2010's	41 (80.39)	24.3611
2020's	9 (17.65)	2.80

Authors

Authors	Studies
Fanurik, D; Hermansen, K; Khatami, H; Kipnes, M; Luo, E; Stein, P	1
Boulton, DW; Griffen, SC; Kasichayanula, S; LaCreta, FP; Li, T; Liu, X; Pfister, M; Shyu, WC; Zhang, W	1
Arechavaleta, R; Chen, Y; Duran, L; Goldstein, BJ; Kaufman, KD; Krobot, KJ; O'Neill, EA; Seck, T; Williams-Herman, D	1
Jermendy, G	1
Nauck, MA	1
Kadokura, T; Keirns, J; Krauwinkel, WJ; Smulders, RA; van Dijk, J; Veltkamp, SA; Zhang, W	1
Colette, C; Comenducci, A; Dejager, S; Monnier, L; Vallée, D	1
Gupta, R; Keshwani, P; Saxena, GN; Srivastava, S	1
Kaneto, H; Katakami, N; Matsuoka, TA; Shimomura, I; Shiraiwa, T; Takahara, M	1
Mateos, JL; Wajchenberg, BL	1
Arai, K; Hirao, K; Hirao, S; Hirao, T; Maeda, H; Sirabe, S; Yamamoto, R; Yamauchi, M	1
Charbonnel, B; Davies, MJ; Engel, SS; Eymard, E; Prabhu, V; Steinberg, H; Thakkar, P; Xu, L	1
Buse, JB; Kahn, SE; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Staten, M; Wexler, D	1
Kimura, H; Masuda, S; Sato, D; Sato, Y	1
Bruce, SS; Connolly, ES; Heyer, EJ; Mergeche, JL	1
Hanaoka, H; Hashimoto, N; Ishikawa, K; Kanatsuka, A; Kobayashi, K; Kuribayashi, N; Onishi, S; Sakurai, K; Sato, Y; Takemoto, M; Terano, T; Uchida, D; Yokoh, H; Yokote, K	1
Arai, K; Hirao, K; Hirao, S; Hirao, T; Kumakura, A; Maeda, H; Shirabe, S; Yamamoto, R; Yamauchi, M	1
Chi, J; Gu, W; Hong, J; Ning, G; Wang, B; Wang, W; Zhang, Y	1
Ahrén, B; Cirkel, DT; Feinglos, MN; Johnson, SL; Perry, C; Stewart, M; Yang, F	1
Persson, U; Steen Carlsson, K	1
Fuller, CS; Gallop, R; Gudipaty, L; Rickels, MR; Rosenfeld, NK; Schutta, MH	1
Inoue, T; Kyou, C; Morishita, K; Ogawa, T; Taguchi, Y; Umayahara, R; Yonemoto, T	1
Aggarwal, N; Amin, NB; Calle, RA; Denney, WS; Le, V; Pall, D; Paragh, G; Riggs, M	1
Fukuda, H; Kato, H; Kondo, A; Nagai, Y; Nakamura, Y; Ohshige, T; Ohta, A; Sada, Y; Sasaki, Y; Sasaoka, T; Tanaka, Y; Tenjin, A; Terashima, Y; Tsukiyama, H	1
Fukatsu, A; Sakai, S; Samukawa, Y; Sasaki, T; Seino, Y; Ubukata, M	1
Betz-Schiff, P; Engel, SS; Golm, GT; Hartley, P; Shankar, RR; Shentu, Y; Sisk, CM	1
Fukase, H; Harigai, M; Iida, S; Ikeda, S; Kasahara, N; Miyata, K; Ohba, Y; Saito, T; Takano, Y; Terao, K	1
Aso, Y; Fukushima, M; Iijima, T; Inukai, T; Jojima, T; Kasai, K; Momobayashi, A; Sagara, M; Suzuki, K	1
Alba, M; Cerdas, S; Chacon, Mdel P; Eliaschewitz, FG; Lavalle-González, FJ; Tong, C	1
Chung, SC; Kim, IJ; Kim, SS; Kim, YI; Lee, KJ; Lee, SJ; Lee, YS; Park, JH	1
Aoki, S; Atsumi, T; Furumoto, T; Inoue, A; Kurihara, Y; Manda, N; Miyoshi, H; Nomoto, H; Oba, K; Tsutsui, H	1
Hashimoto, N; Hasumi, S; Honda, M; Iwamoto, Y; Kasahara, T; Nunome, H; Ohashi, H; Sakura, H; Sasamoto, K; Tomonaga, O; Ujihara, N	1
Cho, JH; Hur, GC; Jang, YH; Jung, CH; Kim, JH; Kim, SH; Lee, BW; Lee, SH; Lee, WJ; Park, CY; Park, SE; Suh, S	1
Hattori, A; Koshizaka, M; Takemoto, M; Tokuyama, H; Yokote, K	1
Bi, Y; Engel, SS; Ji, L; Ji, Q; Jia, W; Lu, J; Mao, A; Mu, Y; Ran, X; Weng, J; Xu, W; Yang, W; Yao, B; Zeng, L; Zhao, B; Zhao, J; Zhou, Z; Zhu, D	1
Ishida, H; Kitaoka, M; Ohsugi, M; Satoh, J; Seino, Y; Shihara, N; Terauchi, Y; Yabe, D; Yamada, Y	1
Ahrén, B; Ambery, P; Carr, MC; Cirkel, DT; Home, PD; Miller, D; Nauck, MA; Rendell, M; Reusch, JEB; Weissman, PN	1
Marcinak, JF; Munsaka, MS; Ohira, T; Smith, N; Watkins, PB	1
Alvey, C; Cutler, DL; Dawra, VK; Hickman, A; Krishna, R; Liang, Y; Sahasrabudhe, V; Saur, D; Shi, H; Terra, SG; Zhou, S	1
Choi, KM; Jang, HC; Kang, ES; Kim, DJ; Kim, ES; Kim, NH; Kim, SJ; Kim, SR; Kim, Y; Lee, MK; Oh, T; You, J	1
Frias, JP	1
Cree-Green, M; Huebschmann, AG; Rafferty, D; Regensteiner, JG; Reusch, JEB; Scalzo, RL; Schauer, I	1
Hansen, HS; Jessen, JB; Johannsen, ML; Munkboel, CH; Styrishave, B	1
Chen, FW; Hou, KJ; Khan, BA; Wu, Z; Wu, ZZ; Zhang, S	1
Balasubramanyam, A; Burch, HB; Buse, JB; Butera, NM; Cohen, RM; Crandall, JP; Kahn, SE; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Rasouli, N; Tiktin, M; Wexler, DJ; Younes, N	1
Bebu, I; Burch, HB; Buse, JB; Cherrington, AL; Fortmann, SP; Green, JB; Kahn, SE; Kirkman, MS; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Phillips, LS; Pop-Busui, R; Steffes, M; Tiktin, M; Tripputi, M; Wexler, DJ; Younes, N	1
Crown, W; Deng, Y; Dhruva, SS; Gandotra, C; Herrin, J; Lyon, TD; McCoy, RG; Noseworthy, P; Polley, EC; Quinto, K; Ross, JS; Shah, ND; Wallach, JD; Yao, X	1
Cauchon, M; Lanthier, L; Mutchmore, A; Plourde, MÉ	1
Brown, K; Donato, AA	2
Bebu, I; de Boer, IH; Ghosh, A; Inzucchi, SE; Ismail-Beigi, F; McGill, JB; Mudaliar, S; Schade, D; Steffes, MW; Tamborlane, WV; Tan, MH; Wexler, DJ; Younes, N	1

Reviews

4 review(s) available for glimepiride and sitagliptin phosphate

Article	Year
[Incretin-based therapy for treating patients with type 2 diabetes]. Orvosi hetilap, 2011, Nov-27, Volume: 152, Issue:48 Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin	2011
The design of the liraglutide clinical trial programme. Diabetes, obesity & metabolism, 2012, Volume: 14 Suppl 2 Topics: Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms	2012
[Liraglutide: new results in the treatment of type 2 diabetes mellitus]. Drugs of today (Barcelona, Spain : 1998), 2012, Volume: 48 Suppl B Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles	2012
Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes. Expert review of endocrinology & metabolism, 2019, Volume: 14, Issue:2 Topics: Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Treatment Outcome	2019

Trials

37 trial(s) available for glimepiride and sitagliptin phosphate

Article	Year
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:5 Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Single-Blind Method; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles	2007
Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:1 Topics: Adolescent; Adult; Benzhydryl Compounds; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Young Adult	2011
Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:2 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles	2011
No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:10 Topics: Adolescent; Adult; Area Under Curve; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Thiophenes; Triazoles	2012
Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose? Diabetes technology & therapeutics, 2012, Volume: 14, Issue:10 Topics: Adamantane; Adult; Aged; Analysis of Variance; Area Under Curve; Basal Metabolism; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrazines; Pyrrolidines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Vildagliptin	2012
Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone. The Journal of the Association of Physicians of India, 2012, Volume: 60 Topics: Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Time Factors; Treatment Outcome; Triazoles	2012
Glimepiride strongly enhances the glucose-lowering effect in triple oral antidiabetes therapy with sitagliptin and metformin for Japanese patients with type 2 diabetes mellitus. Diabetes technology & therapeutics, 2013, Volume: 15, Issue:4 Topics: Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles	2013
Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical tri Diabetologia, 2013, Volume: 56, Issue:7 Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles; Young Adult	2013
Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes care, 2013, Volume: 36, Issue:8 Topics: Adult; Blood Glucose; Comparative Effectiveness Research; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged; Outcome Assessment, Health Care; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles	2013
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-i Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:8 Topics: 1-Deoxynojirimycin; Aged; alpha-Glucosidases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gastrointestinal Agents; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Inositol; Japan; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles	2014
Both glimepiride and high-dose metformin are important for sustained glucose lowering in Japanese type 2 diabetes patients on glimepiride-sitagliptin-metformin therapy: subanalysis of a single-center, open-label, randomized study. Diabetes technology & therapeutics, 2014, Volume: 16, Issue:7 Topics: Administration, Oral; Aged; Aged, 80 and over; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles	2014
Different effects of two dipeptidyl peptidase-4 inhibitors and glimepiride on β-cell function in a newly designed two-step hyperglycemic clamp. Journal of diabetes, 2015, Volume: 7, Issue:2 Topics: Adamantane; Adult; Blood Glucose; Cross-Over Studies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Follow-Up Studies; Glucose Clamp Technique; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Prognosis; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles	2015
HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes care, 2014, Volume: 37, Issue:8 Topics: Aged; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles	2014
Effect of exenatide, sitagliptin, or glimepiride on β-cell secretory capacity in early type 2 diabetes. Diabetes care, 2014, Volume: 37, Issue:9 Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Peptides; Prognosis; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles; Venoms; Young Adult	2014
Low-dose glimepiride with sitagliptin improves glycemic control without dose-dependency in patients with type 2 diabetes inadequately controlled on high-dose glimepiride. Endocrine journal, 2014, Volume: 61, Issue:12 Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Incretins; Insulin; Insulin Secretion; Insulin-Secreting Cells; Japan; Kidney; Male; Middle Aged; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles	2014
Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes. Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:8 Topics: Aged; Benzofurans; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucokinase; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrimidines; Sitagliptin Phosphate; Sulfonylurea Compounds	2015
Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes. Diabetes research and clinical practice, 2015, Volume: 109, Issue:1 Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Liver; Female; Humans; Hypoglycemic Agents; Japan; Lipid Metabolism; Liver; Male; Middle Aged; Overweight; Sitagliptin Phosphate; Sulfonylurea Compounds; Ultrasonography	2015
Absence of Drug-Drug Interactions Between Luseogliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males. Advances in therapy, 2015, Volume: 32, Issue:5 Topics: 1-Deoxynojirimycin; Adult; Antihypertensive Agents; Area Under Curve; Cross-Over Studies; Female; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sorbitol; Sulfonylurea Compounds; Thiazolidinediones; Triazoles	2015
Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial. Drugs & aging, 2015, Volume: 32, Issue:6 Topics: Age Factors; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome	2015
A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs. Drug research, 2016, Volume: 66, Issue:2 Topics: 1-Deoxynojirimycin; Adult; Benzhydryl Compounds; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Interactions; Glucose; Glucosides; Healthy Volunteers; Humans; Hypoglycemic Agents; Inositol; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Pioglitazone; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones; Urine; Young Adult	2016
Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes. Diabetes research and clinical practice, 2015, Volume: 110, Issue:3 Topics: Aged; CD4-Positive T-Lymphocytes; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Flow Cytometry; Humans; Hypoglycemic Agents; Interferon-gamma; Interleukin-17; Interleukin-4; Male; Middle Aged; Prospective Studies; Sitagliptin Phosphate; Sulfonylurea Compounds; T-Lymphocytes, Regulatory; Th17 Cells	2015
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Current medical research and opinion, 2016, Volume: 32, Issue:3 Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Latin America; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome	2016
Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study. Journal of diabetes, 2017, Volume: 9, Issue:4 Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Infections; Male; Metformin; Middle Aged; Nausea; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome	2017
A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters: Sapporo Athero-Incretin Study 1 (SAIS1). PloS one, 2016, Volume: 11, Issue:10 Topics: Adiponectin; Adult; Aged; Aged, 80 and over; Antioxidants; Biomarkers; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Drug Administration Schedule; Endothelium; Female; Glycated Hemoglobin; Hemodynamics; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Prospective Studies; Sitagliptin Phosphate; Sulfonylurea Compounds; Superoxide Dismutase; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult	2016
Effect of gemigliptin on glycaemic variability in patients with type 2 diabetes (STABLE study). Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:6 Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidones; Pyrimidines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Young Adult	2017
Sitagliptin but not alpha glucosidase inhibitor reduced the serum soluble CD163, a marker for activated macrophage, in individuals with type 2 diabetes mellitus. Diabetes research and clinical practice, 2017, Volume: 126 Topics: Aged; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Japan; Macrophages; Male; Middle Aged; Receptors, Cell Surface; Sitagliptin Phosphate; Sulfonylurea Compounds	2017
Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial. Science China. Life sciences, 2017, Volume: 60, Issue:3 Topics: Acarbose; Adult; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome	2017
Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START-J trial). Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:8 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Aging; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Equivalence Trials as Topic; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Incidence; Incretins; Japan; Middle Aged; Reproducibility of Results; Severity of Illness Index; Sitagliptin Phosphate; Sulfonylurea Compounds; Weight Loss	2017
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy. Diabetes research and clinical practice, 2017, Volume: 131 Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Glargine; Male; Pioglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome	2017
Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience. Drug safety, 2018, Volume: 41, Issue:6 Topics: Adult; Aged; Alanine Transaminase; Benzofurans; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Liver; Male; Middle Aged; Sitagliptin Phosphate; Sulfones; Sulfonylurea Compounds	2018
Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects. Clinical pharmacology in drug development, 2019, Volume: 8, Issue:3 Topics: Adolescent; Adult; Bridged Bicyclo Compounds, Heterocyclic; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Female; Glucuronosyltransferase; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Sulfonylurea Compounds; UDP-Glucuronosyltransferase 1A9; Young Adult	2019
Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial. Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:3 Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Equivalence Trials as Topic; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazoles; Republic of Korea; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidines; Treatment Failure	2019
Sitagliptin improves diastolic cardiac function but not cardiorespiratory fitness in adults with type 2 diabetes. Journal of diabetes and its complications, 2019, Volume: 33, Issue:8 Topics: Aged; Blood Glucose; Cardiorespiratory Fitness; Diabetes Mellitus, Type 2; Diastole; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Muscle, Skeletal; Oxidative Phosphorylation; Oxygen Consumption; Placebos; Sitagliptin Phosphate; Sulfonylurea Compounds	2019
Analysis of pharmacoeconomic value of sitagliptin in the treatment of diabetes mellitus. European review for medical and pharmacological sciences, 2021, Volume: 25, Issue:22 Topics: Adult; Aged; Aged, 80 and over; Cost-Benefit Analysis; Diabetes Mellitus; Economics, Pharmaceutical; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds	2021
Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes. The New England journal of medicine, 2022, 09-22, Volume: 387, Issue:12 Topics: Blood Glucose; Comparative Effectiveness Research; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Metformin; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome	2022
Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. The New England journal of medicine, 2022, 09-22, Volume: 387, Issue:12 Topics: Albuminuria; Blood Glucose; Cardiovascular Diseases; Comparative Effectiveness Research; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Drug Therapy, Combination; Dyslipidemias; Glomerular Filtration Rate; Glycated Hemoglobin; Heart Failure; Humans; Hypertension; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Metformin; Microvessels; Sitagliptin Phosphate; Sulfonylurea Compounds	2022
Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial. JAMA internal medicine, 2023, 07-01, Volume: 183, Issue:7 Topics: Adult; Albuminuria; Diabetes Mellitus, Type 2; Disease Progression; Female; Glomerular Filtration Rate; Glucose; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Kidney; Kidney Diseases; Liraglutide; Male; Metformin; Middle Aged; Sitagliptin Phosphate	2023

Other Studies

10 other study(ies) available for glimepiride and sitagliptin phosphate

Article	Year
Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy. Endocrine journal, 2012, Volume: 59, Issue:12 Topics: Administration, Oral; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Female; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Japan; Male; Middle Aged; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles	2012
Effects of a sitagliptin safety alert on prescription behaviour for oral antihyperglycaemic drugs: a propensity score-matched cohort study of prescription receipt data in Japan. Drug safety, 2013, Volume: 36, Issue:8 Topics: Aged; Cohort Studies; Female; Gliclazide; Glyburide; Humans; Hypoglycemic Agents; Japan; Logistic Models; Male; Middle Aged; Patient Safety; Practice Patterns, Physicians'; Propensity Score; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles	2013
Inflammation and cognitive dysfunction in type 2 diabetic carotid endarterectomy patients. Diabetes care, 2013, Volume: 36, Issue:10 Topics: Aged; Cognition Disorders; Diabetes Mellitus, Type 2; Endarterectomy, Carotid; Glyburide; Humans; Hypoglycemic Agents; Inflammation; Logistic Models; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles	2013
Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin. Journal of medical economics, 2014, Volume: 17, Issue:9 Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Health Services; Humans; Hypoglycemic Agents; Life Expectancy; Liraglutide; Male; Metformin; Middle Aged; Models, Economic; Pyrazines; Quality-Adjusted Life Years; Sitagliptin Phosphate; Smoking; Sulfonylurea Compounds; Sweden; Triazoles	2014
Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study. BMC endocrine disorders, 2016, Dec-01, Volume: 16, Issue:1 Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sitagliptin Phosphate; Sulfonylurea Compounds	2016
Oral anti-diabetic drugs as endocrine disruptors in vitro - No evidence for additive effects in binary mixtures. Toxicology in vitro : an international journal published in association with BIBRA, 2021, Volume: 70 Topics: Administration, Oral; Cell Line; Chromatography, Liquid; Drug Interactions; Endocrine Disruptors; Humans; Hypoglycemic Agents; Metformin; Simvastatin; Sitagliptin Phosphate; Steroids; Sulfonylurea Compounds; Tandem Mass Spectrometry	2021
Emulating the GRADE trial using real world data: retrospective comparative effectiveness study. BMJ (Clinical research ed.), 2022, 10-03, Volume: 379 Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Metformin; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome	2022
[In patients with type 2 diabetes on metformin, the addition of which antihyperglycemic class among a sulfonylurea (glimepiride), a DPP-4 inhibitor (sitagliptin), a GLP-1 agonist (liraglutide), or basal insulin (glargine) is the most effective to achieve La Revue de medecine interne, 2023, Volume: 44, Issue:1 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycemic Control; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Liraglutide; Metformin; Sitagliptin Phosphate; Treatment Outcome	2023
In type 2 diabetes, glargine and liraglutide each improved glycemic outcomes at 5 y vs. glimepiride or sitagliptin. Annals of internal medicine, 2023, Volume: 176, Issue:1 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Metformin; Sitagliptin Phosphate; Treatment Outcome	2023
In type 2 diabetes, liraglutide reduced CV events at 5 y vs. glargine, glimepiride, or sitagliptin. Annals of internal medicine, 2023, Volume: 176, Issue:1 Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Glargine; Liraglutide; Sitagliptin Phosphate; Treatment Outcome	2023